SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Update: AbbVie headquarters building in California
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline
The company appears to be terminating the development of two Phase I antibody-drug conjugates in cancer, ABBV-011 and the Pfizer-partnered ABBV-647.
August 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Dubai skyline/Courtesy, iStock, MAGNIFIE
Business
Abu Dhabi, Dubai Serve as Gateway to International Markets for Biopharma
Burjeel Holdings and BridgeBio Pharma ink partnership deal in rare genetic diseases with a plan to set up headquarters in Abu Dhabi.
July 11, 2023
 · 
4 min read
 · 
Lisa Munger
Pictured: Pre-filled injector device/iStock, sunny
First Round of Humira Biosimilar Launches in US
AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
July 3, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: AbbVie sign on a building/courtesy of Ad
Drug Development
AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug
Phase I/II data on AbbVie and Genmab’s recently approved bi-specific antibody in a second cancer indication positions them to talk to regulators about filings to challenge Roche’s Lunsumio.
June 29, 2023
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Analyst pointing to stock chart / iStock
Drug Development
MoonLake Looks to Raise $250M in Stock Offering on Heels of Mid-Stage Data
Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.
June 27, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: T cells attacking and killing cancer cel
FDA
Roche, AbbVie to Compete for Lymphoma Market Share with New BsAbs
With Roche’s FDA approval on Thursday, both companies’ bispecific antibodies will hit the market this summer for relapsed or refractory diffuse large B-cell lymphoma.
June 16, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Judicial gavel and scales of justice/Cou
Policy
AbbVie Files Patent Infringement Lawsuit Against BeiGene’s Brukinsa
The pharma company alleges that BeiGene’s Brukinsa patent, issued on Tuesday, infringes on its patent for Imbruvica to treat patients with slow-growing blood cancer.
June 15, 2023
 · 
2 min read
 · 
Alejandra Manjarrez
Pictured: Mark Cuban/Courtesy of Roy Rochlin/Getty
Business
Coherus to Offer 85% Discount for its Humira Biosimilar
The company’s Humira biosimilar Yusimry will launch in July with a $995 list price. Mark Cuban’s online pharmacy will sell it at a list price of $569.27 plus fees.
June 2, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Blue and white Pfizer sign on building/c
Drug Development
Pfizer’s Antibiotic Combo Clears Phase III, Shows Promise Against Multidrug Resistance
The company’s aztreonam-avibactam matched the cure rate of a meropenem-based regimen in patients with drug-resistant infections.
June 2, 2023
 · 
3 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Drug Development
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
November 29, 2023
 · 
7 min read
FDA
AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
November 27, 2023
 · 
13 min read
Job Trends
Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
November 16, 2023
 · 
11 min read
Business
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
November 1, 2023
 · 
7 min read
Business
BioMed X and AbbVie Start New Research Project in the USA
October 31, 2023
 · 
3 min read
BioMidwest
NEXGEL Secures Supply Agreement with AbbVie
October 30, 2023
 · 
2 min read
Business
AbbVie Reports Third-Quarter 2023 Financial Results
October 27, 2023
 · 
28 min read
Business
Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network
October 24, 2023
 · 
3 min read
BioMidwest
AbbVie’s SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn’s Disease Meets All Primary and Secondary Endpoints
October 15, 2023
 · 
15 min read
Drug Development
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
October 12, 2023
 · 
20 min read
Load More